The CD20 monoclonal antibodies market is expanding rapidly due to increasing prevalence of autoimmune diseases and hematologic cancers such as lymphoma and leukemia. These biologic therapies target CD20 proteins on B-cells, providing effective treatment options. Growing adoption of biosimilars and next-generation antibody therapies is reshaping competitive dynamics. https://www.databridgemarketresearch.com/reports/global-cd20-monoclonal-antibodies-market